These agents include semaglutide (Ozempic for diabetes, Wegovy for obesity), liraglutide (Victoza for diabetes, Saxenda for obesity), dulaglutide (Trulicity, diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for obesity)with tirzepatide being a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist
Los anlogos del GLP-1 amplifican estos mecanismos al prolongar la activacin del receptor, permitiendo un mejor control glucmico y una reduccin significativa de la masa corporal
Managing type 2 diabetes involves frequent glucose monitoring and coordination that extends beyond what telehealth can accommodate
Pharmacol Res 182:106320 Standards of Care in Diabetes2024 (2024) Chronic kidney disease and risk management
Remember, other strategies are well within reach if GLP-1 drugs dont feel right for you
Many eat too many carbs and not enough protein, leading to muscle loss and slower progress